Quavonlimab
Quavonlimab (MK-1308) is a novel anti-CTLA-4 antibody[1].
Product Specifications
CAS Number
2254059-25-9
Product Name Alternative
MK-1308
UNSPSC
12352203
Target
CTLA-4
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/quavonlimab.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Quavonlimab]
Molecular Weight
(144.24 kDa)
References & Citations
[1]Perets R, et al. Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer. Ann Oncol. 2021;32 (3) :395-403.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
NBP3-24086MFV500 0.1 mL
Rabbit Monoclonal Progesterone R/NR3C3 Antibody (PGR/8099R) [mFluor Violet 500 SE]
Sign In for Pricing
View Details GTR15367330 1 Vial
Lentiviral human LIPT1 sgRNA gene knockout kit - Lentiviral human LIPT1 sgRNA gene knockout kit (100)
Sign In for Pricing
View Details